脑肿瘤患者使用直接口服抗凝药相关的颅内出血
该回顾性比较队列研究纳入172例脑肿瘤合并静脉血栓栓塞患者(42例DOAC、131例LMWH),评估12个月颅内出血累积发生率。原发脑肿瘤队列中DOAC组任何颅内出血为0% vs LMWH组36.8%;脑转移瘤队列中DOAC未增加颅内出血风险。结论认为DOAC相对LMWH未增加颅内出血发生率。
要点
- 原发脑肿瘤队列任何颅内出血:DOAC组0% vs LMWH组36.8%(95%CI 22.3-51.3%)。
- 脑转移瘤队列任何颅内出血:DOAC组27.8% vs 依诺肝素组52.9%,DOAC未增加风险。
- 脑转移瘤队列大出血性颅内出血:DOAC组11.1% vs 依诺肝素组17.8%,DOAC未增加风险。
核心结论
- 作者结论认为,在脑转移瘤或原发脑肿瘤患者中,DOAC相对LMWH未增加颅内出血发生率。
研究设计与样本
- 回顾性比较队列研究,共评估172例脑肿瘤合并静脉血栓栓塞患者(42例DOAC、131例LMWH)。
- 所有颅内出血事件的影像学图像均经复核,主要终点为启动抗凝后12个月颅内出血累积发生率。
主要发现
- 原发脑肿瘤队列(n=67)任何颅内出血累积发生率:DOAC组0% vs LMWH组36.8%(95%CI 22.3-51.3%)。
- 原发脑肿瘤队列大出血性颅内出血发生率为18.2%(95%CI 8.4-31.0)。
- 脑转移瘤队列(n=105)任何颅内出血发生率:DOAC组27.8%(95%CI 5.5-56.7%)vs 依诺肝素组52.9%(95%CI 37.4-66.2%),DOAC未增加风险。
- 脑转移瘤队列大出血性颅内出血累积发生率:DOAC组11.1%(95%CI 0.5-40.6%)vs 依诺肝素组17.8%(95%CI 10.2-27.2%),DOAC未增加风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essentials Intracranial hemorrhage (ICH) is common in patients with brain tumors. We compared rates of ICH with DOACs and low molecular weight heparin. DOACs were associated with a lower incidence of ICH in primary brain tumors. DOACs appear safe to administer to patients with brain tumors. SUMMARY: Background Direct oral anticoagulants (DOACs) are efficacious in the treatment of cancer-associated thrombosis but are associated with an increased risk of hemorrhage compared with low-molecular-weight heparin in certain malignancies. Whether the DOACs increase the incidence of intracranial hemorrhage (ICH) in patients with brain tumors is not established. Objectives To determine the cumulative incidence of ICH in DOACs compared with Low-molecular-weight heparin (LMWH) in patients with brain tumors and venous thromboembolism. Patients and methods A retrospective comparative cohort study was performed. Radiographic images for all ICH events were reviewed and the primary endpoint was cumulative incidence of ICH at 12 months following initiation of anticoagulation. Results and conclusions A total of 172 patients with brain tumors were evaluated (42 DOAC and 131 LMWH). In the primary brain tumor cohort (n = 67), the cumulative incidence of any ICH was 0% in patients receiving DOACs vs. 36.8% (95% confidence interval [CI], 22.3-51.3%) in those treated with LMWH, with a major ICH incidence of 18.2% (95% CI, 8.4-31.0). In the brain metastases cohort (n = 105), DOACs did not increase the risk of any ICH relative to enoxaparin, with an incidence of 27.8% (95% CI, 5.5-56.7%) compared with 52.9% (95% CI, 37.4-66.2%). Similarly, DOAC did not increase the incidence of major ICH in brain metastases, with a cumulative incidence 11.1% (95% CI, 0.5-40.6%) vs. 17.8% (95% CI, 10.2-27.2%). We conclude that DOACs are not associated with an increased incidence of ICH relative to LMWH in patients with brain metastases or primary brain tumors.
引用
- Carney BJ, Uhlmann EJ, Puligandla M, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost. 2018. PMID: 30450803. doi:10.1111/jth.14336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。